Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

In multiple cancer types, high tumor mutational burden (TMB) is associated with longer
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …

Abstract Toll-like receptor 9 (TLR9) is a pattern recognition receptor that is predominantly
located intracellularly in immune cells, including dendritic cells, macrophages, natural killer …

Accurate identification of patients with solid tumors likely to respond to immunotherapy is
crucial. Tumor mutational burden (TMB) measures the number of somatic mutations in a …

Combination therapy with inhibitors of cytotoxic T lymphocyte-associated protein (CTLA) 4
and programmed death (PD)-1 has demonstrated efficacy in cancer patients. However, there …

Insertions and deletions constitute the second most important source of natural genomic
variation. Insertions and deletions make up to 25% of genomic variants in humans and are …

Introduction Gastric cancer (GC) is the third leading cause of cancer-related deaths in China
and immunotherapy emerging as a revolutionary treatment for GC recently. Tumor …

Rationale: Diffuse glioma patients have high mortality and recurrence despite multimodal
therapies. This study aims to identify the potential tumor antigens for mRNA vaccines and …

Prediction of driver genes (tumor suppressors and oncogenes) is an essential step in
understanding cancer development and discovering potential novel treatments. We recently …